Bioventus Inc.
Bioventus Inc. Fundamental Analysis
Bioventus Inc. (BVS) shows weak financial fundamentals with a PE ratio of 73.51, profit margin of 1.39%, and ROE of 5.02%. The company generates $0.6B in annual revenue with strong year-over-year growth of 11.89%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 28.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BVS's fundamental strength across five key dimensions:
Efficiency Score
WeakBVS struggles to generate sufficient returns from assets.
Valuation Score
ModerateBVS shows balanced valuation metrics.
Growth Score
ExcellentBVS delivers strong and consistent growth momentum.
Financial Health Score
ModerateBVS shows balanced financial health with some risks.
Profitability Score
WeakBVS struggles to sustain strong margins.
Key Financial Metrics
Is BVS Expensive or Cheap?
P/E Ratio
BVS trades at 73.51 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BVS's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Bioventus Inc. at 3.46 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 3.29 times EBITDA. This is generally considered low.
How Well Does BVS Make Money?
Net Profit Margin
For every $100 in sales, Bioventus Inc. keeps $1.39 as profit after all expenses.
Operating Margin
Core operations generate 7.68 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $5.02 in profit for every $100 of shareholder equity.
ROA
Bioventus Inc. generates $1.11 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bioventus Inc. generates limited operating cash flow of $56.07M, signaling weaker underlying cash strength.
Free Cash Flow
Bioventus Inc. produces free cash flow of $53.51M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.80 in free cash annually.
FCF Yield
BVS converts 9.30% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
73.51
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.02
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.94
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.74
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.05
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How BVS Stacks Against Its Sector Peers
| Metric | BVS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 73.51 | 29.43 | Worse (Expensive) |
| ROE | 5.02% | 800.00% | Weak |
| Net Margin | 1.39% | -20145.00% (disorted) | Weak |
| Debt/Equity | 1.94 | 0.30 | Weak (High Leverage) |
| Current Ratio | 1.74 | 4.64 | Neutral |
| ROA | 1.11% | -17936.00% (disorted) | Weak |
BVS outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bioventus Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
46.54%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-525.69%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-17.15%
Industry Style: Defensive, Growth, Innovation
Declining